Title Credit Start and expiration datessort descending Member price Non-member price
Immunizations 2019: What NPs Who Care for Children Need to Know
1.0 NAPNAP Contact Hour 1.0 Pharmacology Hour Immunization recommendations are updated annually by the CDC. This course will advise NPs about the cutting edge issues in pediatric and adolescent immunizations. The recommended schedule, clarification of the guidelines, newly licensed vaccines and current controversies will be emphasized.
  • 1.00 Contact hours
04/24/2019 to 05/31/2020 $0.00 $10.00
Early Detection and Aggressive Management of Otologic Pathologies in Children with Down Syndrome
This course will review the current recommendations and guidelines related to otologic disease in children with DS. Topics covered will include an overview of the pathologies and etiologies; screening and evaluation guidelines; management options; and the role of the Nurse Practitioner in the primary care setting and beyond. 0.25 NAPNAP Contact Hour, 0 Pharmacology Hour
  • 0.25 Contact hours
05/07/2018 to 05/31/2020 $2.50 $5.00
Expanding Access to Oral Health Care
This course will describe on how to apply an educational model of interprofessional clinical training to improve oral health outcomes in underserved children living in low-income families. 0.25 NAPNAP Contact Hour, 0 Pharmacology Hour
  • 0.25 Contact hours
05/02/2018 to 05/31/2020 $2.50 $5.00
To Clip or Not to Clip: An Update on Pediatric Tongue Tie
This course will include a review of the most recent literature on trends in tongue tie, diagnostic controversies and treatment options for these patients. While lingual frenotomy is the mainstay of treatment for a true tongue tie, this course will also discuss cases when lingual frenotomy may not be warranted and review other treatment options, including working with speech therapists and lactation consultants. 0.25 NAPNAP Contact Hour, 0 Pharmacology Hour
  • 0.25 Contact hours
05/08/2018 to 05/31/2020 $2.50 $5.00
Common Pediatric Sports and Overuse Injuries
Greater than 30 million U.S. children are involved in some kind of organized sport. Many children involved in sports will sustain some type of injury from significant trauma to mild overuse conditions. Many of these issues can affect the pediatric athlete's performance and need to be addressed by an orthopedic expert in a timely manner. The presenter will discuss the most common injuries and conditions in pediatric athletes, including presentation, diagnosis, prognosis and treatment. Conditions include significant fractures of extremities, which may or may not require surgery. Conditions can also include injuries to a pediatric athlete's spine including spondylolysis, and back sprains/strains. 1.25 NAPNAP Contact Hour 0 Pharmacology Hour
  • 1.25 Contact hours
05/04/2018 to 05/31/2020 $12.00 $25.00
Name that Rash
This presentation will focus on visual diagnoses to enhance PNP recognition of common and less common rashes. Highlights from the history and pearls for practice will be reviewed. Plan to review treatment suggestions and highlight rashes of concern that require immediate evaluation in a tertiary care facility. Participants will also review resources that are helpful for practice to enhance diagnostic ability. 1.0 NAPNAP Contact Hour, 0.5 Pharmacology Hour
  • 1.00 Contact hours
05/08/2018 to 05/31/2020 $10.00 $20.00
Inflammatory Markers
This presentation will provide the latest information on inflammatory markers and a comparison between the markers currently available for use in pediatrics. The pathophysiology of the inflammatory response will be presented as well as the physiology of the markers that are released in illness and injury in pediatrics. 1.0 NAPNAP Contact Hour 0 Pharmacology Hour
  • 1.00 Contact hours
05/09/2018 to 05/31/2020 $10.00 $20.00
Opioid Use, Abuse and Prescribing
A national focus on opioid use as a health crisis has heightened public awareness of the extent and severity of opioid abuse. This disease has an impact on the pediatric and adolescent population cared for by pediatric-focused advanced practice registered nurses. The latest evidence related to pediatric and adolescent opioid therapy and addiction management will be presented. This course will include information on federal and state policies that pertain to prescribing controlled substances, medication-assisted treatment, and prescription monitoring programs. Attendees will have exposure to content necessary for controlled substance education that is increasingly tied to ongoing APRN licensure and prescriptive authority.2.25 NAPNAP Contact Hour, 1 Pharmacology Hour, 1 Psychopharmacology Hour, 2.25 controlled substances
  • 2.25 Contact hours
05/07/2018 to 05/31/2020 $25.00 $40.00
Risk Factors & Potential Associated Causes of Developmental, Behavioral, & Mental Health Consequences in Children
1.0 NAPNAP contact hour. This presentation is designed for primary care APRNs to help them identify the children at risk and the red warning flags for DBMH diagnosis. It also provides critical information about the relationship between DBMH diagnosis and the dysregulated stress response system associated with ACES, trauma, and/or toxic stress. Participants will learn the valuable tools to discuss their concerns with the patients and their families, develop interventions, and prevention strategies.
  • 1.00 Contact hours
05/06/2019 to 05/31/2020 $0.00 $10.00
A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients
1.0 contact hour of which 1.0 contain phamacology content. The literature surrounding the use of cystic fibrosis transmembrane conductance regulator-targeted pharmacotherapies in pediatric patients continues to evolve. These therapies represent a departure from symptom management and infection prevention, which have been the mainstay of cystic fibrosis management in pediatrics, to targeting the genetic defect present within these patients. This article reviews the clinical studies evaluating the safety and efficacy of ivacaftor, ivacaftor/lumacaftor, and ivacaftor/tezacaftor. These medications were initially studied in adults and adolescents but have begun to be studied in younger populations. Further investigation into the use of these drugs with different CFTR mutations and in younger age groups will continue to expand the number of patients who can benefit from these therapies. May–June, 2019 Volume 33, Issue 3, Pages 356–364
  • 1.00 Contact hours
04/18/2019 to 06/30/2020 $0.00 $10.00
Radiographic Interpretation for the Hospitalized Child
This course will teach a systematic approach to reviewing pediatric radiographs and expected placement of central lines, chest tubes, feeding tubes and endotracheal tubes. Pediatric chest x-rays will be reviewed. 1.25 NAPNAP Contact Hour, 0 Pharmacology Hour
  • 1.25 Contact hours
06/01/2018 to 06/30/2020 $12.00 $25.00
Delivering Evidence Based Pediatric Pain Management
The course will discuss on how to recognize current evidence related to pediatric pain and how to choose pharmacological and nonpharmacological therapies for managing pain.1.75 NAPNAP Contact Hour, 0.25 Pharmacology Hour, 0.25 Controlled substances
  • 1.75 Contact hours
06/12/2018 to 06/30/2020 $20.00 $30.00
Sleep Medications
How comfortable are you in coaching children and families with chronic sleep problems? This session explores complex sleep history, initial interventions and pharmacologic options for pediatric sleep management in primary care settings. We discuss the efficacy, tolerability, and safety profiles of both prescribed and over-the-counter medication options, as well as important patient-, family- and clinic-specific factors to consider in sleep management. 1.25 NAPNAP Contact Hour, 1.25 Pharmacology Hour, 1.25 Psychopharmacology Hour
  • 1.25 Contact hours
06/11/2018 to 06/30/2020 $12.00 $25.00
Clinical Practice Recommendations for Pediatric Dyslipidemia
1.0 Contact Hours, 0.25 Pharmacology. The leading cause of mortality in the United States is atherosclerotic cardiovascular disease (ASCVD). Atherosclerotic lesions begin during childhood and can place individuals at greater risk for ASCVD. Providers play an active role in preventing the progression of risk factors and future ASCVD events through appropriate clinical management of genetic and acquired dyslipidemias in the pediatric population. Health care providers need to be aware of current recommendations related to screening for dyslipidemia, lifestyle modification strategies, pharmacologic treatment, and guidelines for ongoing monitoring. Most patients with mild to moderate dyslipidemia can be managed by a primary care provider.It is imperative that providers understand the pathophysiology, screening methods, and available treatment options to effectively manage the condition. Frequent reassessment of family history and adherence to lifestyle modifications and pharmacologic interventions is essential for effective treatment. Journal of Pediatric Health Care (2019) 33, volume 4, 494-504.
  • 1.00 Contact hours
06/13/2019 to 08/31/2020 $0.00 $10.00
Chest Pain and Syncope 2018
The course will describe causes of chest pain and syncope. 0.5 NAPNAP Contact Hour 0 Pharmacology Hour
  • 0.50 Contact hours
12/31/2018 to 12/31/2020 $5.00 $10.00

Pages